ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Form 6-K — Jun 15, 2026
Ascentage Pharma Group International reported multiple positive clinical updates for its core assets olverembatinib and lisaftoclax at the EHA 2026 Congress. The data highlights deep and durable responses in chronic myeloid leukemia (CML) and promising efficacy in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Olverembatinib demonstrated a 76.2% complete cytogenetic response rate in second-line CML patients and significantly outperformed control therapies in a head-to-head trial, achieving a 54.3% major molecular response rate at six months versus 10.0% for prior TKIs.
Key figures
- Lisaftoclax orr cll sll
- 62.5%
- Olverembatinib mmr rate
- 47.6%
- Olverembatinib ccyr rate
- 76.2%
- Lisaftoclax cr cri rate aml
- 72%
- Lisaftoclax mrd neg rate aml
- 61%
- Lisaftoclax median pfs cll sll
- 23.9 months
- Olverembatinib cr cri rate ph all
- 94.4%
- Olverembatinib mmr vs control 6mo
- 54.3% vs 10.0%
- Olverembatinib mmr vs control 12mo
- 57.14% vs 21.43%
- Olverembatinib mrd neg rate ph all
- 63.0%
- Olverembatinib lisaftoclax orr pediatric
- 88.9%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.